Phase Ib Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2017
At a glance
- Drugs CVA 21 (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms MITCI
- Sponsors Viralytics
- 09 Aug 2017 Planned number of patients changed from 60 to 59.
- 23 Jul 2017 Planned number of patients changed from 26 to 60.
- 23 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History